Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABP NASDAQ:ADTX NASDAQ:ATNF NASDAQ:AYTU On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABPAbpro$0.25+0.6%$0.24$0.15▼$13.00$19.65M0.036.12 million shs3.32 million shsADTXAditxt$1.03-1.9%$1.16$0.81▼$7,210.00$5.13M1.51322,565 shs158,654 shsATNF180 Life Sciences$2.81-2.1%$3.02$0.66▼$17.75$16.97M0.3822.03 million shs11.34 million shsAYTUAytu BioPharma$2.35+1.7%$2.33$0.95▼$2.85$21.10M0.22103,451 shs65,570 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABPAbpro0.00%-1.57%+2.94%+11.46%+24,509,900.00%ADTXAditxt0.00%-0.96%0.00%-24.26%-99.98%ATNF180 Life Sciences0.00%-14.85%-20.62%+165.09%+55.25%AYTUAytu BioPharma0.00%+6.82%-2.08%+32.02%-6.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABPAbproN/AN/AN/AN/AN/AN/AN/AN/AADTXAditxtN/AN/AN/AN/AN/AN/AN/AN/AATNF180 Life Sciences0.9175 of 5 stars0.02.00.00.03.81.70.6AYTUAytu BioPharma3.6837 of 5 stars3.52.00.03.43.30.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABPAbpro 3.00Buy$4.001,531.99% UpsideADTXAditxt 0.00N/AN/AN/AATNF180 Life Sciences 0.00N/AN/AN/AAYTUAytu BioPharma 3.00Buy$10.00325.53% UpsideCurrent Analyst Ratings BreakdownLatest ADTX, ABP, ATNF, and AYTU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/14/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)7/29/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)7/12/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)7/1/2025AYTUAytu BioPharmaLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.006/30/2025AYTUAytu BioPharmaAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.006/27/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)6/11/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABPAbpro$180K109.16N/AN/A($0.29) per share-0.85ADTXAditxt$130K39.46N/AN/A($1.52) per share-0.68ATNF180 Life SciencesN/AN/AN/AN/A$2.91 per shareN/AAYTUAytu BioPharma$81M0.26N/AN/A$4.64 per share0.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABPAbpro-$7.23MN/A0.00∞N/AN/AN/A-241.16%N/AADTXAditxt-$34.45MN/A0.00∞N/A-206,431.38%-316.98%-80.88%11/17/2025 (Estimated)ATNF180 Life Sciences-$6.17M-$15.07N/A∞N/AN/A-141.25%-80.77%11/12/2025 (Estimated)AYTUAytu BioPharma-$15.84M-$0.72N/A∞N/A2.37%3.51%0.91%9/25/2025 (Estimated)Latest ADTX, ABP, ATNF, and AYTU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/25/2025Q4 2025AYTUAytu BioPharma-$0.02N/AN/AN/AN/AN/A8/14/2025Q2 2025ADTXAditxtN/A-$3.45N/A-$3.45N/AN/A8/13/2025Q2 2025ABPAbproN/A-$0.04N/A-$0.05N/AN/A7/23/2025Q2 2025ATNF180 Life SciencesN/A-$0.30N/A-$0.30N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABPAbproN/AN/AN/AN/AN/AADTXAditxtN/AN/AN/AN/AN/AATNF180 Life SciencesN/AN/AN/AN/AN/AAYTUAytu BioPharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABPAbproN/A0.150.15ADTXAditxtN/A0.020.02ATNF180 Life SciencesN/A0.580.58AYTUAytu BioPharma0.271.030.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABPAbpro23.30%ADTXAditxt15.54%ATNF180 Life Sciences4.07%AYTUAytu BioPharma33.49%Insider OwnershipCompanyInsider OwnershipABPAbpro20.80%ADTXAditxt0.01%ATNF180 Life Sciences38.20%AYTUAytu BioPharma3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABPAbpro1580.17 million63.49 millionN/AADTXAditxt604.98 million4.98 millionNo DataATNF180 Life Sciences76.04 million3.73 millionNo DataAYTUAytu BioPharma1608.98 million8.65 millionNot OptionableADTX, ABP, ATNF, and AYTU HeadlinesRecent News About These CompaniesArmistice Capital Overcomes Novel Ruling to Win Aytu Stock CaseAugust 14, 2025 | news.bloomberglaw.comNLake Street Sees Big Upside for Aytu Biosciences (AYTU) After EXXUA AcquisitionJuly 23, 2025 | msn.comAytu Boosts Liquidity with Eclipse Loan ExtensionJuly 2, 2025 | msn.comLake Street Initiates Coverage of Aytu BioPharma (AYTU) with Buy RecommendationJuly 2, 2025 | msn.comAscendiant Capital Initiates Coverage of Aytu BioPharma (AYTU) with Buy RecommendationJune 30, 2025 | msn.comAytu BioPharma, Inc.: Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA - FinanzNachrichten.deJune 27, 2025 | finanznachrichten.deAytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM)June 25, 2025 | accessnewswire.comAAytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA (TM) - MorningstarJune 24, 2025 | morningstar.comMAytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM)June 23, 2025 | accessnewswire.comACEO & Director of Aytu BioPharma Joshua Disbrow Buys 77% More SharesJune 14, 2025 | finance.yahoo.comAytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class ...June 10, 2025 | morningstar.comMAytu BioPharma Announces Closing of Upsized At the…June 10, 2025 | pharmiweb.comPAytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization PlanJune 9, 2025 | accessnewswire.comAAytu BioPharma to commercialise Exxua for MDD in the USJune 9, 2025 | pharmaceutical-technology.comPAytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in ...June 8, 2025 | seekingalpha.comAytu BioPharma, Inc.: Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common StockJune 6, 2025 | finanznachrichten.deAytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common StockJune 6, 2025 | accessnewswire.comAAytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United StatesJune 6, 2025 | accessnewswire.comAAytu BioPharma Third Quarter 2025 Earnings: Beats ExpectationsMay 16, 2025 | finance.yahoo.comAytu BioPharma, Inc. (NASDAQ:AYTU) Q3 2025 Earnings Call TranscriptMay 16, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADTX, ABP, ATNF, and AYTU Company DescriptionsAbpro NASDAQ:ABP$0.25 +0.00 (+0.57%) As of 08/29/2025 03:59 PM EasternAbpro Holdings Inc. is a biotechnology company. The company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.Aditxt NASDAQ:ADTX$1.03 -0.02 (-1.90%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.02 -0.01 (-0.97%) As of 08/29/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.180 Life Sciences NASDAQ:ATNF$2.81 -0.06 (-2.09%) As of 08/29/2025180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.Aytu BioPharma NASDAQ:AYTU$2.35 +0.04 (+1.73%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.35 0.00 (0.00%) As of 08/29/2025 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant With Shares Near Highs, Here's to Watch in Broadcom's Q3 Report Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
